Kexing Biopharm and Hinova Forge Alliance to Expand Global Market Reach
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced this week a strategic alliance with compatriot...
Kintor Pharmaceutical’s KX-826 Shows Promising Results in Alopecia Phase III Trial
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced positive topline results from the long-term safety Phase...
Junshi Biosciences Receives NMPA Approval for JS212 in Advanced Solid Tumors
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced receiving clearance from the...
Hengrui’s Trastuzumab Rezetecan Nears 8th Breakthrough Therapy Designation
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its trastuzumab rezetecan (SHR-A1811), an...
Fosun’s Henlius Receives FDA Orphan Drug Designation for HER2-Targeting HLX22
On March 19, 2025, Fosun Pharmaceutical (SHA: 600196) announced that its subsidiary, Henlius, has received...
Paratek Pharmaceuticals to Acquire Optinose for $330 Million
Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ: OPTN) announced a definitive merger agreement on March 19,...
Boji Medical’s Huasheng Transfers Glucosamine Sulfate Capsules Technology to Panlong
On March 20, 2025, Boji Medical Technology Co., Ltd (known as Boji Biomedicals) (SHE: 300404)...
Oxford BioTherapeutics Partners with Roche on Cancer Therapeutics Discovery
On March 19, 2025, Oxford BioTherapeutics announced a multiyear collaboration with Roche (SWX: ROG, OTCMKTS:...
Joyo Pharma’s JYP0035 Receives Clinical Trial Approval for Breast Cancer Treatment
On March 14, 2025, Joyo Pharma announced that its independently developed next-generation, highly selective Class...
CDE Announces 92nd Batch of Reference Preparations for Generic Drug Evaluation
China’s Center for Drug Evaluation (CDE) has released the 92nd batch of reference preparations for...
HutchMed’s 2024 Financial Report Shows Dip in Revenue Amid Oncology Product Growth
China-based HutchMed (NASDAQ: HCM, HKG: 0013) released its 2024 financial report, revealing a total revenue...
Servier and Black Diamond Therapeutics Ink Global Deal for BDTX-4933
French pharmaceutical company Servier and US-based Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) announced a strategic...
NMPA Seeks Public Input on Drug Trial Data Protection Measures
On March 19, 2025, China’s National Medical Products Administration (NMPA) released draft measures and procedures...
Telix Pharmaceuticals Gains Brazilian Approval for Prostate Cancer Diagnostic Agent TLX591-CDx
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) announced receiving clearance from the Brazilian Health Regulatory Agency...
Distinct Healthcare Files for Hong Kong IPO to Expand Integrated Medical Services
Shenzhen-based Distinct Healthcare Holdings Limited, a comprehensive medical service provider with integrated online and offline...
Pfizer Restructures China Operations to Boost Growth and Innovation
US-based pharmaceutical giant Pfizer Inc. (NYSE: PFE) announced a significant leadership and organizational restructuring in...
CDE’s 2024 Annual Drug Review Report Shows Continued Growth in Regulatory Filings
The Center for Drug Evaluation (CDE) released its 2024 annual drug review report, highlighting continued...
Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production
China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in...
GE Healthcare and NVIDIA Expand Partnership to Advance Autonomous X-ray and Ultrasound Technologies
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced an...
Tonghua Dongbao Initiates Phase III Trial for Insulin Degludec, Liraglutide Combo in Type 2 Diabetes
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has initiated a Phase III clinical study for its...